Telix Pharmaceuticals (ASX:TLX): FDA Approval for Pixclara Expands US Imaging Portfolio

Aditi Sarkar

14 September 2026 06:59 PM AEST

Telix Pharmaceuticals (ASX:TLX): FDA Approval for Pixclara Expands US Imaging Portfolio

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Telix Pharmaceuticals (ASX:TLX) received US FDA approval for Pixclara for PET imaging in patients with glioma.
Pixclara is the first FDA-approved FET-PET imaging agent for glioma in the United States.
The approval adds another commercial diagnostic product alongside Telix's established Illuccix franchise.
Commercial rollout, reimbursement, clinical adoption and pipeline development are now important areas to monitor.

Telix Pharmaceuticals (ASX:TLX) has reached an important regulatory milestone after securing United States Food and Drug Administration approval for Pixclara, its brain-cancer imaging agent.

The approval expands Telix's commercial diagnostic portfolio in the United States and provides another potential Revenue stream alongside Illuccix, its established prostate-cancer imaging product. Attention now shifts from regulatory clearance towards commercial rollout, reimbursement and adoption by cancer treatment centres.

Recent Development

On 14 September 2026, Telix Pharmaceuticals (ASX:TLX) announced that the FDA had approved Pixclara, or floretyrosine F-18, also known as 18F-FET, for positron emission tomography imaging.

The agent is indicated to help differentiate recurrent or progressive glioma from treatment-related changes in adult and paediatric patients aged one month and older when used alongside other diagnostic evaluations.

According to Telix, Pixclara is the first FDA-approved FET-PET imaging drug for glioma and the only approved radiopharmaceutical imaging product for the disease in the United States. The approval followed the FDA's earlier acceptance of the product's new drug application.

Clinical Rationale

Gliomas can be difficult to assess using conventional imaging because MRI may not always clearly distinguish tumour recurrence from changes caused by previous treatment.

Pixclara targets amino-acid transport mechanisms that are over-expressed in glioma cells, potentially providing clinicians with additional information when evaluating suspected disease progression.

There are approximately 24,000 new glioma cases in the United States each year, and gliomas account for a significant proportion of malignant brain tumours. This creates a defined clinical market for more specialised imaging tools.

Commercial Opportunity

For Telix Pharmaceuticals (ASX:TLX), Pixclara broadens a US commercial platform already established through Illuccix.

The company can potentially utilise parts of its existing manufacturing, distribution and commercial infrastructure to support the Pixclara launch, which may reduce some of the complexity associated with introducing an entirely new product platform.

The addition of another FDA-approved diagnostic also supports Telix's broader strategy of developing a portfolio of targeted radiopharmaceutical products across multiple areas of oncology.

Actual commercial contribution will depend on factors including reimbursement, pricing, clinical uptake and the speed at which imaging centres incorporate the product into routine practice.

Pipeline Expansion

Telix is also conducting a Phase 3 study aimed at extending the use of the imaging agent into brain metastases.

If successful, expansion beyond glioma could increase the potential addressable market and strengthen Pixclara's role within the company's precision medicine portfolio.

For Telix Pharmaceuticals (ASX:TLX), progress across this study and other therapeutic radiopharmaceutical programmes will remain important as the Business seeks to broaden beyond its existing diagnostic franchises.

What Investors May Watch Next

The commercial rollout of Pixclara is now one of the most important near-term developments.

Investors may monitor reimbursement decisions, pricing, adoption among US cancer centres and the pace at which the product contributes to group revenue.

Performance of Illuccix also remains important because it continues to anchor Telix's commercial operations in the United States.

Other areas to watch include progress in the Phase 3 brain-metastases programme, Manufacturing capacity, additional regulatory approvals in international markets and advancement of the company's therapeutic radiopharmaceutical pipeline.

Risks

Regulatory approval does not guarantee rapid commercial adoption. Pixclara's revenue contribution will depend on reimbursement coverage, physician awareness, availability at imaging centres and competitive dynamics.

Radiopharmaceutical products also require specialised manufacturing and distribution because of their limited shelf life and operational complexity.

Clinical development remains another risk. Additional indications may not achieve required trial outcomes or regulatory approval, while scaling multiple commercial and development programmes can increase operating and Capital requirements.

Key Takeaways

Telix Pharmaceuticals (ASX:TLX) has expanded its US commercial portfolio with FDA approval for Pixclara, providing the company with another approved diagnostic product alongside Illuccix.

The approval strengthens Telix's position in targeted radiopharmaceutical imaging and addresses a clinical need in distinguishing glioma progression from treatment-related changes.

The next stage will depend on execution. Reimbursement, adoption, manufacturing capacity and progress in additional indications will determine how significantly Pixclara contributes to the company's longer-term growth.

FAQs

Q: What is Pixclara?

A:A PET imaging agent used in the assessment of glioma.

Q: When did Pixclara receive FDA approval?

A:On 14 September 2026.

Q: What does Pixclara help clinicians identify?

A:It helps distinguish glioma progression from treatment-related changes.

Q: What other approved product does Telix sell in the US?

A:Illuccix.

Q: What should investors watch next?

A:Commercial adoption, reimbursement and pipeline progress.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.